Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis

American Journal of Hematology

Volumn 83, Issue 11, 2008, Pages 876-878

  Alsaleh, Khalid A ^a   Al Nasser, Sami M A ^a   Bates, Shannon M ^a   Patel, Ameen ^a   Warkentin, Theodore E ^a,b   Arnold, Donald M ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ARGATROBAN; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; IMMUNOGLOBULIN G; PROTEIN ANTIBODY; THROMBOCYTE FACTOR 4; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; WARFARIN;

ADULT; AMNESIA; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISORIENTATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRIORITY JOURNAL; SEPSIS; SEROTONIN RELEASE; SLURRED SPEECH; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOSIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE;

ANTICOAGULANTS; AUTOANTIBODIES; BLOOD PLATELETS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MIDDLE AGED; PLATELET FACTOR 4; POLYSACCHARIDES; THROMBOCYTOPENIA;

EID: 55549113246     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21273     Document Type: Article

References (21)

1. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001;135:502-506.
2. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-1840.
3. Harenberg J, Jorg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004;89:1017-1018.
4. Kuo KH, Kovacs MJ. Fondaparinux: A potential new therapy for HIT. Hematology 2005;10:271-275.
5. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008;99:208-214.
6. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008;99:779-781.
7. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356:2653-2655.
8. Rauova L, Zhai L, Kowalska MA, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: Diagnostic and therapeutic implications. Blood 2006;107:2346-2353.
9. Refaai MA, Warkentin TE, Axelson M, et al. Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin "flushes." Thromb Haemost 2007;98:1139-1140.
10. Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003;348:1067-1069.
11. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007;21:589-607.
12. Jackson MR, Neilson WJ, Lary M, et al. Delayed-onset heparin-induced thrombocytopenia and thrombosis after intraoperative heparin anticoagulation-four case reports. Vasc Endovascular Surg 2006;40:67-70.
13. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002;136:210-215.
14. Smythe MA, Stephens JL, Mattson JC. Delayed-onset heparin-induced thrombocytopenia. Ann Emerg Med 2005;45:417-419.
15. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis. Blood 2005;106:2710-2715.
16. Greinacher A, Alban S, Omer-Adam MA, et al. Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008;122:211-220.
17. Greinacher A, Gopinadhan M, Gunther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006;26:2386-2393.
18. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106:3791-3796.
19. Warkentin TE, Lim W. Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. J Thromb Haemost 2008;6:1243-1246.
20. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
21. Warkentin TE, Hayward CP, Smith CA, et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992;120:371-379.